Latest Insights & News
View All Articles →Why anti-fibrotic drugs succeed in cell culture but fail in animals: the translational gap in PK/PD, microenvironment, immunology, and how PCLS bridges it.
Vicore's Buloxibutid (C21): first-in-class oral AT2R agonist. AIR Ph2a FVC +216 mL at 36 weeks. FDA Fast Track. ASPIRE Ph2b (NCT06588686) ongoing.
AI digital pathology cuts pathologist variability in IPF/MASH fibrosis scoring. Compares Ashcroft/METAVIR with pixel-level %Area via HALO and QuPath.
MASH (Diet-Induced)
CCl4-Induced Liver Fibrosis
Bleomycin-Induced Pulmonary Fibrosis
UUO Mouse Model
Bleomycin-Induced Scleroderma
DSS-Induced Colitis
Browse by Disease Area
Find preclinical models for your indication
Liver / Hepatic
MASH/NASH, CCl₄, MCD, and other liver fibrosis models
View models →Lung / Pulmonary
Bleomycin-induced IPF, silica, and other pulmonary fibrosis models
View models →Kidney / Renal
UUO, adenine nephropathy, ADR/FA, and other CKD progression models
View models →Heart / Cardiac
Myocardial infarction, pressure-overload, and cardiac fibrosis models
View models →Skin / Dermal
Bleomycin SSc, hypochlorite, and systemic sclerosis models
View models →GI / Inflammatory Bowel
DSS colitis, TNBS, and chronic IBD/fibrosis models
View models →For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.